Cytomegalovirus prophylaxis in solid organ transplant recipients

Transplantation

Volumn 61, Issue 9, 1996, Pages 1279-1289

  Patel, Robin ^a   Snydman, David R ^b   Rubin, Robert H ^c   Ho, Monto ^d   Pescovitz, Mark ^e   Martin, Maureen ^f   Paya, Carlos V ^a  

^a MAYO CLINIC   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; IMMUNOGLOBULIN; OKT 3;

ALLOGRAFT; ANTIVIRAL ACTIVITY; CYTOMEGALOVIRUS; GRAFT SURVIVAL; HUMAN; IMMUNOPROPHYLAXIS; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; REVIEW; SEROCONVERSION; TISSUE TYPING; VACCINATION; VIRUS INFECTION; VIRUS TRANSMISSION;

ACYCLOVIR; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; IMMUNIZATION, PASSIVE; TRANSPLANTATION; VACCINATION;

EID: 0029976967     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199605150-00001     Document Type: Review

References (58)

1. Ho M. Advances in understanding cytomegalovirus infection after transplantation. Transplant Proc 1994; 26: 7.
2. Chou S, Kim DY, Norman DJ. Transmission of cytomegalovirus by pretransplant leukocyte transfusions in renal transplant candidates. J Infect Dis 1987; 55: 565.
3. Rook AH. Interactions of cytomegalovirus with the human immune system. Rev Infect Dis 1988; 10 (suppl 3): S460.
4. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 4: 467.
5. Arnold JC, Portmann BC, O'Grady JG, Naoumov NV, Alexander GJM, Williams R. Cytomegalovirus infections persists in the liver graft in the vanishing bile duct syndrome. Hepatology 1992; 16: 285.
6. Van den Berg AP, Klimpmaker IJ, Haagsma EB, et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991; 164: 265.
7. Mazzulli T, Rubin RH, Ferraro MJ, et al. Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS. J Clin Microbiol 1993; 31: 2924.
8. Delgado R, Lumbreras C, Alba C, et al. Low predictive value of polymerase chain reaction for diagnosis of CMV disease in liver transplant recipients. J Clin Microbiol 1992; 30: 1876.
9. Patel R, Smith TF, Espy M, et al. Detection of cytomegalovirus (CMV) in sera of liver transplant recipients. J Clin Microbiol 1994; 32: 1431.
10. Portela D, Patel R, Larson-Keller JJ, et al. OKT3 treatment for allograft rejection is a risk factor for CMV disease in liver transplantation. J Infect Dis 1995; 171: 1014.
11. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123: 18.
12. Sayers MH, Anderson KC, Goodnough LT, et al. Reducing the risk for transfusion-transmitted cytomegalovirus infections. Ann Intern Med 1992; 116: 55.
13. Balfour HH Jr, Welo PK, Sachs GW. Cytomegalovirus vaccine trial in 400 renal transplant candidates. Transplant Proc 1985; 17: 81.
14. Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne liver virus vaccine on cytomegalovirus disease after renal transplant. Ann Intern Med 1991; 114: 525.
15. Britt W, Fay J, Seals J, et al. Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice. J Infect Dis 1995; 171: 18.
16. Riddell SR, Greenberg PD. Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones. Curr Top Microbiol Immunol 1994; 189: 9.
17. Farrell HE, Shellam GR. Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J Gen Virol 1991; 72: 149.
18. Bjøro K, Frølond SS, Yun Z, et al. Hepatitis C infection in patients with hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331: 1607.
19. Greger B, Vallbracht A, Kurth J, et al. The clinical value of CMV prophylaxis by CMV hyperimmune serum in kidney transplant patients. Transplant Proc 1986; 18: 1387.
20. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987; 317: 1049.
21. Fassbinder W, Ernst W, Hanke P, et al. Cytomegalovirus infections after renal transplantation: effect of prophylactic hyperimmunoglobulin. Transplant Proc 1986; 18: 1393.
22. Kasiske BL, Heim-Duthoy KL, Tortorice KL, et al. Polyvalent immune globulin and cytomegalovirus infection after renal transplantation. Arch Intern Med 1989; 149: 2733.
23. Cofer JB, Morris CA, Sutker WL, et al. A randomized double-blind study of the effect of prophylactic immune globulin on the incidence and severity of CMV infection in the liver transplant recipient. Transplant Proc 1991; 23: 1525.
24. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin for prophylaxis in liver transplantation. A randomized double-blind placebo-controlled trial. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1993; 10: 984.
25. Saliba F, Arulnaden JL, Gugenheim J, et al. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplant Proc 1989; 21: 2260.
26. Snydman DR, Werner BG, Dougherty NN, et al. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Transplant Proc 1994; 26: 23.
27. Bailey TC, Ettinger NA, Storch GA, et al. Failure of high-dose oral acyclovir with or without globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med 1993; 95: 273.
28. Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients - a meta-analysis. Clin Transplant 1994; 8: 10.
29. Snydman DR. [Letter]. Clin Transplant (in press).
30. Conti DJ, Freed BM, Gruber SA, et al. Prophylaxis of primary cytomegalovirus disease in renal transplant patients. Transplantation 1993; 56: 491.
31. Tsevdt J, Snydman DR, Pauker SG, Durand-Zaleski I, Werner BG, Levey AS. Which renal transplant recipients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis. Transplantation 1991; 52: 259.
32. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1182.
33. Martin FM, Manez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 58: 779.
34. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70.
35. Balfour HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl Med 1989; 320: 1381.
36. Saliba F, Eyraud D, Samuel D, et al. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant Proc 1993; 25: 1444.
37. Green M, Reyes J, Nour B, et al. Randomized trial of ganciclovir followed by high dose oral acyclovir vs. ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis. Transplant Proc 1994; 26: 173.
38. Frey DJ, Matas AJ, Gillingham KJ, et al. Sequential therapy - a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 1992; 54: 50.
39. Littler E, Stuart AD, Cree MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral analogue ganciclovir. Nature 1992; 358: 160.
40. Aguado JM, Gomez-Sanchez MA, Lumbreras C, et al. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother 1995; 39: 1643.
41. Rondeau E, Bourgeon B, Peraldi MN, et al. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1993; 8: 858.
42. Dunn DL, Gillingham KJ, Kramer MA, et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 1994; 57: 876.
43. Cohen AT, O'Grady JG, Sutherland S, Sallie R, Tan K-C, Williams R. Controlled trial of prophylactic versus therapeutic use of ganciclovir in liver transplantation in adults. J Med Virol 1993; 40: 5.
44. Nakazato PZ, Burns W, Moore P, Garcia-Kennedy R, Cox K, Esquivel C. Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and ganciclovir. Transplant Proc 1993; 25: 1935.
45. Duncan DR, Grgurich WF, Laceno AT, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994; 150: 146.
46. Winston DJ, Winn D, Shaked A, Busuttil RW. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 1995; 346: 43.
47. Boivin G, Erice A, Crane DD, Dunn DL, Balfour HH. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 1993; 168: 322.
48. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis 1995; 171: 1431.
49. Bailey TC. Prevention of cytomegalovirus disease. Sem Respir Infect 1993; 8: 225.
50. Braitman A, Swerdel MR, Olsen SJ, et al. Evaluation of SQ 34,514: pharmacokinetics and efficacy in experimental herpes-virus infections in mice. Antimicrob Agents Chemother 1991; 35: 1464.
51. Rubin RH, Tolkoff-Rubin NE. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother 1993; 37: 619.
52. Singh N, Yu VL, Mietes L, et al. High-dose acyclovir compared with short course preemptive therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994; 120: 375.
53. Cagle PT, Buttone G, Holland VA, et al. Semiquantitative measurement of cytomegalovirus DNA in lung and heart-lung transplant patients by in vitro DNA amplification. Chest 1992; 101: 93.
54. Koskinen PK, Nieminen MS, Mattila SP, Häyry PJ, Lautenschlager IT. The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients. Transplantation 1993; 55: 547.
55. Stratta RJ, Shaefer MS, Cushing KA, et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 1992; 127: 55.
56. Metselaar HJ, Rothbarth PH, Brouwer RM, et al. Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection. Transplantation 1989; 48: 264.
57. Steinmuller DR, Novick AC, Streem SB, Graneto D, Swift C. Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection. Transplantation 1990; 49.
58. Pillay D, Ali AA, Liu SF, Kops E, Sweny P, Griffiths PD. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients. Transplantation 1993; 56: 103.